Last reviewed · How we verify
BR5402A-1
BR5402A-1 is a small molecule that targets the HMG-CoA reductase enzyme.
BR5402A-1 is a small molecule that targets the HMG-CoA reductase enzyme. Used for Hypercholesterolemia.
At a glance
| Generic name | BR5402A-1 |
|---|---|
| Also known as | Placebo of BR5402A |
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Drug class | HMG-CoA reductase inhibitor |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
By inhibiting HMG-CoA reductase, BR5402A-1 aims to reduce cholesterol production in the liver, thereby lowering low-density lipoprotein (LDL) cholesterol levels. This mechanism is similar to that of statins, but BR5402A-1 may have a different pharmacokinetic profile and potentially fewer side effects.
Approved indications
- Hypercholesterolemia
Common side effects
- Muscle pain
- Liver enzyme elevation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |